Cancer Drug Pricing Hits $480,000 Annually, Signaling Industry's New Floor
Source: NYT > Business (paywall)
Revolution Medicines' Rasonque normalizes half-million-dollar price tags for incremental oncology advances. The drug extends pancreatic cancer survival by months, not years. This pricing reflects a structural shift: pharmaceutical companies extract maximum value from a fragmented U.S. healthcare system that lacks price negotiation leverage, and insurance reimbursement rarely questions six-figure annual costs. Payers have stopped resisting ultra-premium pricing, making it the default starting position rather than an outlier. That will cascade through reimbursement expectations across the cancer drug pipeline.